FDA Experts Push For Wider Anti-Overdose Drug Availability

Law360, Washington (April 12, 2012, 8:18 PM EDT) -- While experts at a U.S. Food and Drug Administration meeting Thursday advocated broader availability for a prescription painkiller overdose antidote, they emphasized the need for additional clinical trials before releasing the drug to the public, saying past data don't conform to regulatory needs.

Although local programs have already been distributing naloxone kits in 15 states and the District of Columbia, according to a Centers for Disease Control and Prevention report, qualified clinical data that could be used to support FDA approval to distribute naloxone as a prescription...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.